Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What CAGR And Valuation Are Anticipated For The Theranostics Market?
The size of the theranostics market has experienced substantial expansion in the past few years. Its growth is projected to progress from $111.1 billion in 2024 to $122.98 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 10.7%. Factors such as advances in molecular imaging, migration towards value-based healthcare, and integration with oncology have supported the growth during the historic period.
In the forthcoming years, a quick expansion is predicted for the theranostics market size, reaching $184.94 billion in 2029 with a 10.7% compound annual growth rate (CAGR). The predicted growth during the forecast period is due to factors such as an increase in precision medicine initiatives, wider applications beyond oncology, an aging population and chronic diseases, advancements in biomarker discovery and government backing and funding. Noteworthy trends for the forecast period consist of regulatory support, the emergence of companion diagnostics, a heightened concentration on cancer theranostics, patient involvement and awareness, and technological integration.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10823&type=smp
What Market Forces Are Contributing To The Growth Of The Theranostics Market?
The surge in cancer cases is projected to fuel the theranostics market’s expansion. Cancer, which involves uncontrollable cell growth affecting various organs, is a major cause of morbidity and mortality globally. Theranostics, a fusion of therapy and diagnosis, holds considerable promise for managing cancer and other chronic diseases. Its merging of diagnostic and treatment capabilities facilitates personalized, targeted therapies, suggesting an avenue for healthcare innovation. Therefore, the increase in cancer incidence will promote the theranostics market’s expansion. For example, the National Cancer Institute (NCI), an American government body within the National Institutes of Health (NIH) that specializes in cancer research, prevention, and treatment, stated in January 2022 that about 5.4% of the population or 18.1 million individuals in the United States have survived cancer. It also stated that 623,405 people were living with metastatic forms of breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma in 2022, a figure that is forecasted to grow to 693,452 by 2025. Consequently, the increasing incidence of cancer is propelling the theranostics market.
Which Segmentation Factors Are Critical In The Theranostics Market Analysis?
The theranosticsmarket covered in this report is segmented –
1) By Disease Type: Neurological Disorders; Cardiovascular Diseases; Immunological Disorders; Oncology Diseases; Other Diseases
2) By Technology: Polymerase Chain Reaction; Immunohistochemistry; In-Situ Hybridization; Sequencing; Other Technologies
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
Subsegments:
1) By Neurological Disorders: Alzheimer’s Disease; Parkinson’s Disease; Multiple Sclerosis; Epilepsy; Other Neurological Disorders
2) By Cardiovascular Diseases: Coronary Artery Disease; Heart Failure; Atrial Fibrillation; Hypertension; Other Cardiovascular Diseases
3) By Immunological Disorders: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Psoriasis; Other Immunological Disorders
4) By Oncology Diseases: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Oncology Diseases
5) By Other Diseases: Infectious Diseases; Metabolic Disorders; Genetic Disorders; Other Diseases
How Are Global Trends Impacting The Development Of The Theranostics Market?
Renowned corporations active in the theranostics market are channeling their efforts towards the advancement of technologically sophisticated solutions, including theranostics clinical trials. Their primary objective is to elevate personalized medicine and improve patient outcomes by fusing diagnostics and therapeutics into a single treatment method. Theranostics clinical trials, research studies assessing the concurrent application of diagnostic tests and targeted therapies, strive to refine treatment plans for each patient. The trials endeavor to gauge the efficacy of certain treatments tied to unique patient biomarkers to augment personalized medicine. For instance, during May 2024, BAMF Health, a cancer treatment center located in the US, unveiled the COMBAT Trial, officially named “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). The trailblazing features of the trial encompass a swift activation process via BAMF Health’s BAMF RapAct program, facilitating the launch in a mere seven weeks. The study also centers on employing innovative radiopharmaceuticals that target the Gastrin-Releasing Peptide receptor (GRPR), with the intention of enhancing treatment alternatives for patients confined to limited therapeutic paths.
Which Organizations Are At The Forefront Of The Theranostics Market?
Major companies operating in the theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc, Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Helmholtz Centre for Infection Research, Radiopharm Theranostics Ltd, Alpha- Theranostics, UNIVERZITET U NOVOM SADU, Cardio-Theranostics LLC, Curium, SoFi Technologies Inc., Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc, Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, The Bristol-Myers Squibb Company, Danaher Corporation, MilliporeSigma, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report
Which Region Is Leading Innovation In The Theranostics Market?
North America was the largest region in the global theranostics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=10823&type=smp
Browse Through More Reports Similar to the Global Theranostics Market 2025, By The Business Research Company
Tumor Ablation Therapy Devices Global Market Report 2025
Negative Pressure Wound Therapy Global Market Report 2025
Aromatherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model